As of Feb 27
| -0.51 / -0.12%|
The 20 analysts offering 12-month price forecasts for Biogen have a median target of 420.00, with a high estimate of 495.00 and a low estimate of 330.00. The median estimate represents a +2.54% increase from the last price of 409.59.
The current consensus among 26 polled investment analysts is to Buy stock in Biogen. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.